Live feed08:00:00·342dPRReleasevia QuantisnowTyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)ByQuantisnow·Wall Street's wire, on your screen.TYRA· Tyra Biosciences Inc.Health Care
